How Can We Help You?

Quick Info:

Find a Doctor Specialties (800) 213-3284

Go To Home PageBack

Fallopian Tube Cancer Trials

Select Clinical Trial

Protocol Number: NRG-GY005/ Ovarian/ Fallopian Tube/ Peritoneal

Protocol Title: Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)

Eligibility: Patient population 18 Years and older with confirmed ovarian cancer, peritoneal cancer or fallopian tube cancer that has returned after receiving chemotherapy with drugs that contain platinum (platinum-resistant) or continued to grow while being treated with platinum-based chemotherapy drugs (platinum-refractory).

Contact Information: (910) 715-2200

____________________________________________________________________________________________

Protocol Number: ImmunoGen/GOG 3045

Protocol Title: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator’s Choice of Chemotherapy in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression

Eligibility: Women ≥ 18 years of age with a confirmed diagnosis of high-grade serous EOC, primary peritoneal cancer, or fallopian tube cancer.  Patients must have platinum-resistant disease.

Contact Information: (910) 715-2200

Specialties
Clara McLean House
Make a Donation
News & Events